Canertinib Dihydrochloride-impurities | Pharmaffiliates

canertinib dihydrochloride and its Impurities

Canertinib Dihydrochlorideis an irreversible tyrosine-kinase inhibitor with activity against EGFR HER-2 and ErbB-4 By 2015, Pfizer had discontinued development of the drug. It is an experimental drug candidate for the treatment of cancer. Canertinib Dihydrochloride has been reported as a substrate for OATP1B3.. Reference standards of Canertinib Dihydrochloride API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

Displaying 1 results for canertinib dihydrochloride Impurities
PA 03 08000

Canertinib Dihydrochloride - API Standards

Canertinib Dihydrochloride


  • Catalogue No.:PA 03 08000

  • CAS :

    289499-45-2

  • Molecular Formula : C24H27Cl3FN5O3

  • Molecular Weight : 558.86